Drugs / ICHORCUMAB
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03080987 | Jun 2017 → Jun 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02949206 | Nov 2016 → Aug 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03251482 | Nov 2017 → Nov 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICHORCUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298002 ↗ |
| Known as | JNJ-375 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298002 ↗ |
| Known as | JNJ-64179375 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03251482 ↗ |
| Known as | JNJ-9375 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298002 ↗ |
| Action | Inhibit | “Thrombin inhibitor” CHEMBL4298002 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4298002 ↗ |
| Route | Intravenous | “single ascending Intravenous dose of JNJ-64179375” NCT02949206 ↗ |
| Target | F2 | “Thrombin inhibitor” CHEMBL4298002 ↗ |